Strattera vs Wellbutrin for Adult ADHD: Which Fits You Better

If stimulants aren’t the right fit, the non-stimulant conversation for adult ADHD usually lands on two names: Strattera (atomoxetine) and Wellbutrin (bupropion). They sound interchangeable, but one is FDA-approved for ADHD and the other is an antidepressant borrowed for it.

Both drugs work on your brain’s recycling pumps for chemical messengers, and that’s where they part ways. The Strattera prescribing information describes atomoxetine as a selective blocker of the norepinephrine transporter. The Wellbutrin XL label describes bupropion as inhibiting the reuptake of both dopamine and norepinephrine. That difference in precision, one pump versus two, shapes much of what follows.

Stimulants remain the benchmark for good reason. A 2018 Lancet Psychiatry meta-analysis pooled 133 double-blind trials and found amphetamines and methylphenidate reduced adult ADHD symptoms more than placebo, with amphetamines supported as the preferred first choice in adults. The results are real, and the science is well-established.

But stimulants don’t fit everyone, and at Siggy we believe choosing between the alternatives deserves the same evidence-first care rather than a coin flip. This guide compares Strattera and Wellbutrin on what the trials show, how they feel, how long they take, and where each carries risk. The choice between them comes down to your whole clinical picture, not brand preference.

What This Page Covers

• How Strattera and Wellbutrin Differ at a Glance
• What the Evidence Shows in Adults
• Side Effects Compared
• Safety Warnings That Shape the Choice
• How Long Each Takes to Work
• Can You Take Strattera and Wellbutrin Together?
• How Prescribers Choose Between Them

How Strattera and Wellbutrin Differ at a Glance

The two labels and a Cochrane bupropion review for adult ADHD lay out the basic differences.

Feature	Strattera (Atomoxetine)	Wellbutrin (Bupropion)
FDA approval for ADHD	Yes, adults and children 6 and up	No, off-label use
Other approved uses	None	Depression, seasonal affective disorder
Usual adult dosing	40 mg start, 80 mg target, 100 mg max	150 to 450 mg a day in ADHD trials
Biggest safety concerns	Heart rate, blood pressure, liver injury	Seizures, blood pressure
Controlled substance	No	No

Both come as generics, and both are taken once or twice a day, depending on the formulation and your prescriber’s plan. Brand-name Strattera itself has been discontinued, and an FDA Federal Register notice confirmed the decision wasn’t made for safety or effectiveness reasons.

What the Evidence Shows in Adults

Strattera’s adult evidence is larger. In two randomized adult trials with 280 and 256 participants, atomoxetine beat placebo over 10 weeks on both inattentive and hyperactive-impulsive symptoms.

Wellbutrin’s evidence is real but thinner. The Cochrane review found six trials with 438 adults, all using long-acting bupropion at 150 to 450 mg a day. Bupropion reduced symptom severity and raised the chance of clinical improvement, but the reviewers rated the overall evidence as low quality because of small samples and risk of bias.

When the Lancet network meta-analysis compared everything together, the two landed in nearly the same place for adults. Clinician-rated symptom improvement versus placebo was similar for bupropion and atomoxetine, but bupropion’s estimate was far less precise, with a much wider range of plausible effects. In plain terms, the averages look alike, and Strattera’s average is simply better established.

Side Effects Compared

Strattera’s side effects are well documented. In the label’s pooled adult trials, nausea affected 26% of people on atomoxetine versus 6% on placebo, dry mouth 20% versus 5%, decreased appetite 16% versus 3%, and insomnia 15% versus 8%. Erectile dysfunction and urinary hesitation were also more common, and 11.3% of adults stopped because of side effects compared with 3% on placebo.

Bupropion’s profile leans more activating. In the depression trials summarized on the Wellbutrin XL label, dry mouth, nausea, insomnia, dizziness, tremor, sweating, and ringing in the ears were among the reactions seen more often than with placebo. Weight loss was more common than weight gain.

The Lancet analysis reflects that difference. Atomoxetine was less well tolerated than placebo in adults, measured by dropouts due to side effects, while Cochrane found bupropion’s side-effect dropouts were similar to placebo, with low certainty. For a closer look at the first weeks on atomoxetine, see our guide to Strattera side effects in the first month.

Safety Warnings That Shape the Choice

Each drug carries warnings that can make it the wrong choice for some people.

For Strattera, the label lists:

• Increases in heart rate and blood pressure, with checks at baseline and after dose changes
• Rare but severe liver injury, with instructions to stop if jaundice or signs of liver damage appear
• Urinary hesitancy or retention
• A boxed warning about suicidal thoughts in children and adolescents; a similar analysis in adults didn’t show increased risk

For Wellbutrin, the label lists:

• Dose-related seizure risk, with a contraindication for seizure disorders, bulimia or anorexia, and abrupt withdrawal from alcohol, benzodiazepines, barbiturates, or antiseizure drugs
• Increases in blood pressure
• A boxed warning about suicidal thoughts in young adults, which applies to all antidepressants

Both can trigger mania in people with bipolar disorder, and neither should be combined with an MAOI. If you have chest pain, fainting, a seizure, or thoughts of harming yourself, call 911 or call or text 988.

How Long Each Takes to Work

Timelines differ in shape more than in speed. In a bupropion XL trial of 162 adults, 53% responded by week 8 versus 31% on placebo, and the gap was already significant at week 2.

Atomoxetine tends to build gradually. An atomoxetine response review found it can start working within 1 to 2 weeks, with response continuing to increase for up to 24 weeks or longer. Judging it at week 3 can mean judging it too early.

Can You Take Strattera and Wellbutrin Together?

It’s possible, but it changes the math. Atomoxetine is cleared mainly by an enzyme called CYP2D6, and the FDA’s interaction table classifies bupropion as a strong CYP2D6 inhibitor. When another strong inhibitor, paroxetine, was given with atomoxetine, atomoxetine exposure rose 6.5-fold, according to the Strattera label.

That’s why the Strattera label calls for a longer, 4-week interval between dose increases when a strong CYP2D6 inhibitor is on board. Combining the two is a prescriber decision that needs closer monitoring of heart rate, blood pressure, and side effects.

How Prescribers Choose Between Them

No single rule decides it, but a few patterns come up often:

• ADHD without depression, where an FDA-approved non-stimulant is preferred, may point toward Strattera.
• ADHD alongside depression may point toward bupropion, since it’s approved for depression.
• A seizure history or eating disorder rules out bupropion.
• Severe heart or blood vessel disease, narrow-angle glaucoma, or a history of pheochromocytoma rules out Strattera.
• Other medications matter, especially anything that affects CYP2D6.

Your prescriber will also weigh blood pressure, sleep, sexual side effects, and what you’ve already tried. For how a third non-stimulant compares, see our guide to guanfacine for ADHD, sleep, and focus.

Your prescriber should make the final call between these two, and because both take weeks to show their full effect, the decision doesn’t end with the first prescription.

Because both drugs build slowly, a weekly note on focus, mood, sleep, and side effects helps you and your prescriber judge whether the medication is working before you decide it isn’t.

Strattera offers FDA approval and the deeper adult evidence base, and Wellbutrin offers an off-label option that also treats depression, with seizure risk and a weaker evidence base as the tradeoffs. For a wider view, see our guide to non-stimulant ADHD medication options.

Ready to take control of your mental health? Start your anonymous intake with Siggy and get your plan reviewed by a licensed prescriber.

This article is for education only and isn’t a substitute for personal medical advice. Talk with your own clinician before starting, changing, or stopping any medication.